Acrongenomics Inc. WKN: A0B9TS Ein Wert mit Zukunft. - 500 Beiträge pro Seite

[Wuscher]

Nanobiotechnologieunternehmen mit revolutionärer Produktpipeline
Leser des Artikels: 3269

In der aktuellen Ausgabe des PENNYSTOCK REPORTs empfehlen die Analysten die Acrongenomics Inc. (WKN: A0B9TS / ISIN: US0050151028), ein Biotechnologie-Unternehmen, das spezialisiert ist auf die Entwicklung und den Vertrieb von innovativen Diagnostiklösungen.


Neo-EpCAM Cancer Detection Kit

Dieses Produkt wird zukünftig für die Erkennung von Krebs am Ausgangspunkt genutzt werden. Es ermöglicht, die Ergebnisse sensitiver und genauer zu ermitteln. Die neue Technologie verringert die Testdauer um bis zu 75% und senkt die Laborkosten deutlich. Dies bedeutet einen besseren Service sowie aussagekräftigere Ergebnisse.


Die Nano-JETA™ Plattform

Diese Plattform hat das Potenzial, den molekularen Diagnostiksektor zu revolutionieren und neu zu definieren. Die Ergebnisse werden im Schnitt zehnmal so schnell ermittelt als bei allen herkömmlichen PCR-Systemen. Im Gegensatz zu anderen gleichartigen Tests werden weniger Schritte und weniger Enzymmaterial für die Durchführung der Tests benötigt. Somit können die Ergebnisse bis zu viermal schneller ausgelesen werden.


Strategische Allianzen

Acrongenomics hat eine strategische Allianz mit Eurogenet Laboratories geschlossen. Im Vordergrund steht für Acrongenomics die Qualitätskontrolle, um ein zuverlässiges, sicheres System mit einer hohen Performance zu schaffen.


Fazit:

Sollte Acrongenomics im nächsten Schritt die kommerzielle Produktion verwirklichen, wäre hier ein erhebliches Marktpotenzial zu erschließen und eine zukünftige Marktführerschaft nicht ausgeschlossen. Wenn sich die Produkte am Markt durchsetzen, wären Kurse im zweistelligen Bereich vertretbar. Die Analysten des PENNYSTOCK REPORTs sehen ihr erstes Kursziel bei 5 Euro.


Lesen Sie kostenlos die komplette Analyse zur Acrongenomics Inc. und das Interview mit dem President und CSO auf www.pennystockreport.de

Autor: PennyStock, 08:30 31.03.05

Ich habe mir mal einige zugelegt.

[Wuscher]

Gibt es meinungen zu diesen Wert ?
MFG

[Wuscher]

Heute wider im Plus

[Wuscher]

Es ist nicht leicht an neuen Infos ran zu
kommen.
Kann da jemand ein paar Tipps geben.
mfg

[Wuscher]

Läuft doch recht gut.

[Wuscher]

Junge Junge
Muß man erst mit der Peitsche knallen
oder geht hier noch was über den Verstand
Schaut den Chart
Macht euch schlau !
Das Baby geht und geht und keiner nimmt es war.
Hier ist echte kOHLE ZU MACHEN AUF sichere art und
weise.
Das Baby ist ja noch nicht mal ansatzweise entdeckt
Jeder ist seines Glückes Schmied
mfg

[Wuscher]

Und wieder dick im Plus

ACRON GENOMICS INC
A0B9TS / FSE


3,39 EUR
0,00
05.04.05 50,85 17:49
15.04.05
21.440 3,80 EUR
Über 3% im Plus 0,20
5,56%
3,00
5,56% 57,00
Über 3% im Plus 6,15
12,09 % EditierenVerkaufen
LimitKommentar
Löschen

[js200]

@WUSCHER

Acrongenomics Inc. Further Develops Its Nano-JETA Platform

Friday , March 11, 2005 09:30 ET

ATHENS, Greece, Mar 11, 2005 (BUSINESS WIRE) --Acrongenomics Inc. (OTCBB:AGNM) a Research and Development company focused in the field of nanobiotechnology is exploring future prospects by evaluating the technology behind existing implementations of PCR, ELISA and Real Time PCR.

According to our market research, current applications reveal certain limitations, including problems with efficiencies and cost effectiveness. Acrongenomics Inc. endeavors to overcome these limitations by introducing nanotechnology into molecular biology. Nanotechnology is beginning to generate substantial new insights into how biological systems function and is believed to hold potential advances in both the pharmaceuticals and health care industries.

Acrongenomics Inc. believes that its first application, the Neo-EpCAM(TM) Cancer detection kit provides enhanced performance as a result of its ongoing Nano-JETA(TM) platform, which combines nanotechnology with molecular biology and applies in PCR, enzyme reactions - including universal ELISA Detection Systems - and Real Time PCR.

In total, 97 different tissue samples from patients suffering from laryngeal cancer, and 82 different tissue samples from patients suffering from breast cancer were used for standardization, evaluation, validation and characterization of our Neo-EpCAM(TM) cancer detection kit. A characterization and evaluation report for Neo-EpCAM(TM) has been completed in universal PCR and ELISA.

By advancing our know-how in nanotechnology, we managed to apply our Nano-JETA(TM) platform on the detection of more markers and viral targets such as Neo-EpCAM(TM), HER1, HER2, HER3, and HER4, with the incorporation of the appropriate primers. A characterization and evaluation report has been completed in PCR and ELISA.

-- 750 tests were performed in colon and breast cancer samples

-- 750 tests were performed in colon and laryngeal cancer samples

-- 250 tests were also performed in breast and laryngeal cancer samples

In essence, Nano-JETA(TM) Platform shows a potential in eliminating all known limitations of current technologies. These developments led to the reshaping of both Conventional PCR and ELISA, to Nano-JETA(TM) PCR, and Universal Nano-JETA(TM) ELISA respectively without compromising sensitivity, specificity and reliability.

Realizing the potential applications of our Nano-JETA(TM) Platform is of crucial importance in understanding its diversity. There is a large number of possible permutations waiting to be explored, and therefore Acrongenomics has evolved Nano-JETA(TM) Platform in Real-Time PCR application for "markers" such as EpCAM, HER1, HER2, and vEGF by conducting clinical validation trials in 400 samples of breast, colon, lung and ovarian cancer anticipating completion by the end of March 2005. Preliminary indications reveal precision, accuracy, specificity and reproducibility.

By evolving our proprietary technology, we have currently achieved a typical Real-Time PCR in 47 seconds without compromising sensitivity, specificity and reliability.

Nano-JETA(TM) platform as an application for Real Time PCR uses common Real Time PCR equipment revealing qualitative results even from the first cycle reaching maximum performance at the eighth cycle.

In addition, with such achievements and in order to strengthen our position, we have decided to conduct independent validation studies in U.S.

Molecular diagnostic testing is the fastest-growing segment of the in vitro diagnostics industry. The last four years, clinical market for molecular diagnostic products has increased from $1 billion in 2000 to 2,8 billion in 2004 and sales are expected to exceed $5 billion by 2008 (Biotechnology Associates). So profitable is the molecular diagnostics market that pharmaceutical and biotechnology companies are highly focused in developing tests that can be used to guide prescribing, and individualize patient treatment.

SOURCE: Acrongenomics Inc.

Acrongenomics Inc.
Investor Relations
Tom Skarpelos, 800-689-8181
[e-mail]
www.acrongen.com

Copyright Business Wire 2005

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


04/15/2005 (16:25 ET) AGNM: New 52-Wk High @ $5.100 up 6.25% - Knobias



04/14/2005 (10:00 ET) AGNM: New 52-Wk High @ $4.950 up 7.61% - Knobias



04/11/2005 (09:50 ET) AGNM: New 52-Wk High @ $4.740 up 7.73% - Knobias



04/05/2005 (09:56 ET) AGNM: New 52-Wk High @ $4.550 up 2.25% - Knobias



04/04/2005 (14:35 ET) AGNM: New 52-Wk High @ $4.320 up 1.89% - Knobias



04/01/2005 (12:15 ET) AGNM: New 52-Wk High @ $4.300 up 2.87% - Knobias



03/31/2005 (15:47 ET) AGNM: Filed New Form NT 10-K, Annual Report to be Filed Late - Edgar



03/31/2005 (10:50 ET) AGNM: New 52-Wk High @ $4.250 up 1.19% - Knobias



03/30/2005 (15:15 ET) AGNM: New 52-Wk High @ $4.150 up 5.06% - Knobias



03/11/2005 (09:30 ET) Acrongenomics Inc. Further Develops Its Nano-JETA Platform - Business Wire



02/09/2005 (06:07 ET) AGNM: Filed New Form 8-K, Material Event Disclosure - Edgar



01/25/2005 (09:55 ET) AGNM: New 52-Wk High @ $3.590 up 7.16% - Knobias



01/18/2005 (10:06 ET) AGNM: New 52-Wk High @ $3.300 up 3.12% - Knobias



01/06/2005 (10:10 ET) AGNM: New 52-Wk High @ $3.250 up 14.04% - Knobias



01/06/2005 (09:18 ET) AGNM: Reported on by InvestSource - Knobias



12/08/2004 (15:22 ET) Acrongenomics Inc. Announcement - Business Wire



11/22/2004 (03:55 ET) bellwetherreport.com: Bellwether Report Issues Post Bell Alerts on Four Potential Growth Opportunties - M2 Communications



11/19/2004 (14:57 ET) AGNM: Announces $1M Private Placement - Knobias



11/19/2004 (14:54 ET) Acrongenomics Inc. Announces $1,000,000 Private Placement to Fund Ongoing Operations - Business Wire



11/19/2004 (01:00 ET) AGNM: Intends $1M Private Placement of 400K Common Shares - Knobias



11/12/2004 (15:03 ET) AGNM: Filed New Form 10QSB, Quarterly Report - Knobias



10/26/2004 (08:12 ET) AGNM: Acquires 4 Patents - Knobias



10/26/2004 (06:11 ET) AGNM: Filed New Form 8-K - Edgar



08/24/2004 (06:04 ET) AGNM: Filed New Form 10QSB/A - Edgar



08/16/2004 (17:34 ET) AGNM: Filed New Form 10QSB - Edgar

[Wuscher]

• Acrongenomics endeavors to be regarded as an innovative company with high-standard quality products, that is respected by the global scientific community and regarded as an influential player in the corporate community.

• To eventually be recognized as one of the foremost research and development centers globally, as well as to stimulate even further collaboration with the scientific community in areas such as gene expression, proteomics, functional genomics, fluorescent system applications, as well as molecular prospecting and evolution.

• Our leading role in the field of nanobiotechnology, research, production and commercialization of innovative products, compels us to shift our development in order to maintain our pole position.

• To enjoy a rapid growth but at the same time be able to effectively combine science with business and ethics.

• Acrongenomics is committed in providing the market with high-value exclusive products that are designed to serve the common good.

• We strongly believe that operational discipline is always required for further quality improvement.

• Our philosophy encourages the scientific team and gives access to some of the most advanced technology and biological information available on the market. This environment certainly optimizes the scientific outcome of their work, while at the same time increases their rate of productivity.

• We intend to establish a strong foundation for scientific research, and together with our administrative expertise, cost-efficiency and innovative high market value tools there is no doubt that this vision will be real.

Der Chart dazu ist einfach nur Geil.

Auf Fette Gewinne!!
MFG

[Wuscher]

Heute


im Plus

mfg

[Wuscher]

Knacken wir heute
die 4 Euro Marke?

Ich denke schon.
mfg

[Wuscher]

Ich stelle mir gerade die Frage
WAS MUß EIGENTLICH PASSIEREN
Damit jemand merkt wo Geld
verdient wird.
Das baby nimt ein Höchst Stand nach den anderen
Und keinen interessiet es.
Da wird lieber in ein Wert geblieben der
....... ist
in der hoffnung das wird schon.
Hallo Hallo

Hier ist der Kohle bringer!!!!!!!!!

20%
in zwei Wochen

Sag mal einer wer mehr hatte!!!???


so leude Seht Schaut und
TRAUT EUCH REIN
Geld Stinkt nicht.
MFG

[Wuscher]

Das Baby macht
richtig spass

[Wuscher]

Heute bei 4.20€
mfg

[Wuscher]

Einfach fantastisch wie
das Baby rennt.

Keiner eine Meinung dazu??
mfg

[dfage]

hier ne neue Nachricht (läuft und läuft ohne push) :

ACRONGENOMICS Inc. SHOWS RESULTS FROM ITS FIRST CLINICAL VALIDATION STUDY ON Nano-JETA™ PLATFORM
May 6, 2005 10:17 AM Eastern

ATHENS, Greece-May 04, 2005--Acrongenomics Inc. (OTCBB:AGNM) a Research and Development company focusing in the field of nanobiotechnology has managed to reshape key IVD molecular applications such as PCR, ELISA and Real Time PCR through its Nano-JETA™ technology platform, by integrating nanotechnology into molecular biology.

Acrongenomics Inc. recently conducted a clinical validation study at EuroGENET Laboratories SA to further establish its Nano-JETA™ technology platform in regards to Real Time PCR application, the Nano-JETA™ Real Time PCR.

The objectives of the study were:

a) to validate the Nano-JETA™ Real Time PCR via the detection of Ep-CAM gene and ß-actin (internal control) in peripheral blood of patients suffering from breast and colon cancer (patients were histologically and cytologically verified), and

b) to evaluate the Nano-JETA™ technology platform in comparison to conventional Real Time PCR methodology for Ep-CAM and ß-actin respectively in regards to stability, sensitivity, specificity and reproducibility.

The study was designed intentionally incorporating the most difficult parameters such as blind control, multi-centre clinical validation study, with variant and unidentified patient status (primary or metastatic status, follow up or on treatment)

The original number of patient samples was 250 but according to EuroGENET Labs Quality Control acceptance criteria, only 236 patient samples qualified as appropriate for participating in the study. The remaining 14 samples were rejected. Therefore, RNA was extracted from fresh blood samples of 236 patients suffering from breast and colon cancer. cDNA was produced according to both Nano-JETA™ and conventional cDNA protocols.

Conventional Real Time PCR and Nano-JETA™ Real Time PCR were performed for Ep-CAM and ß-actin. The average cycles required for Real Time PCR and Nano-JETA™ Real Time PCR completion were 45 and 13 respectively. Furthermore, the total reaction volume required for Real Time PCR and Nano-JETA™ Real Time PCR was 25µl and 8µl respectively.

Research results revealed that in the case of ß-actin (internal control) both protocols exhibited 100% specificity.
ß-actin was detectable from the 16th to 18th cycle when using common Real-Time PCR, while only 1 single cycle was required with Nano-JETA™ Real-Time PCR.

In regards to sensitivity, common Real-Time PCR detected 104 cancer cells, while requiring 22 to 32 cycles. In contrast, Acrongenomics’ Nano-JETA™ Real-Time PCR exhibited sensitivity of 10² cancer cells, with the use of 1 single cycle.

By using common Real-Time PCR, Ep-CAM was detected in 28 samples out of 236 (11,9% positive) and it was not found in 208 samples (88,1% negative) showing sensitivity of 104 cancer cells as noted before.

On the other hand, by using Nano-JETA™ Real-Time PCR, Ep-CAM was detected in those same 28 samples – but it was also detected in 22 additional samples (21,2%). It was not detected in 186 samples out of 236 (78,8% negative), exhibiting sensitivity of 10² cancer cells. This was due to the fact that Nano-JETA™ Real-Time PCR is one hundred times more sensitive than conventional Real Time PCR.

Acrongenomics believes that the capabilities and performance of the Nano-JETA™ technology platform developed by Acrongenomics Inc. could be regarded as a breakthrough application in the diagnostic market for stability, sensitivity, specificity and reproducibility.

[Wuscher]

Da wächst etwas ganz großes heran.
mfg

[Wuscher]

Heute geht es weiter
GEN NORDEN
Das Baby ist einfach nur GUT.
mfg

[Wuscher]

Heute 4.40€

[Wuscher]

Und es geht weiter gen Norden.

[Wuscher]

Das Baby kennt nur eine Richtung!!!!!!

NORDEN

mfg

[Wuscher]

Wie ein Fels in der Brandung.
mfg

[dfage]

@ wuscher

ich bin am Freitag raus nachdem der Kurs zwischenzeitlich in USA unter Druck stand. 52 % +. Jetzt warte ich erst mal ab wann der Kurs sich wieder stabilisiert.Hoffe Du hast auch Deine Gewinne realisiert